Coronary artery disease is more severe in patients with primary hyperparathyroidism.


Journal

Surgery
ISSN: 1532-7361
Titre abrégé: Surgery
Pays: United States
ID NLM: 0417347

Informations de publication

Date de publication:
01 2020
Historique:
received: 30 01 2019
revised: 27 04 2019
accepted: 22 05 2019
pubmed: 2 11 2019
medline: 6 5 2020
entrez: 1 11 2019
Statut: ppublish

Résumé

Primary hyperparathyroidism is associated with an increased cardiovascular mortality, but mechanisms underlying this association are unclear. The goal of this study was to evaluate coronary artery calcifications via the coronary calcification score in primary hyperparathyroidism patients, to compare with control subjects, and to identify risk factors for high to intermediate risk coronary calcification scores (coronary calcification score >100). Cross-sectional study of primary hyperparathyroidism patients without a history of coronary artery disease, diabetes, or severe, chronic kidney disease. Coronary calcification scores were compared with a cohort of population-based control subjects. The mean coronary calcification score was 120 ± 344 in 130 primary hyperparathyroidism patients. The coronary calcification score was >100 in 27 patients (21%). When compared with control subjects, the percentage of positive coronary calcification scores was similar in primary hyperparathyroidism patients (53% vs 50%); however, positive coronary calcification scores were at the 67 Positive coronary calcification scores were greater in primary hyperparathyroidism patients than in population-based control subjects. These study data may provide new criteria for parathyroidectomy in patients with primary hyperparathyroidism.

Sections du résumé

BACKGROUND
Primary hyperparathyroidism is associated with an increased cardiovascular mortality, but mechanisms underlying this association are unclear. The goal of this study was to evaluate coronary artery calcifications via the coronary calcification score in primary hyperparathyroidism patients, to compare with control subjects, and to identify risk factors for high to intermediate risk coronary calcification scores (coronary calcification score >100).
METHOD
Cross-sectional study of primary hyperparathyroidism patients without a history of coronary artery disease, diabetes, or severe, chronic kidney disease. Coronary calcification scores were compared with a cohort of population-based control subjects.
RESULTS
The mean coronary calcification score was 120 ± 344 in 130 primary hyperparathyroidism patients. The coronary calcification score was >100 in 27 patients (21%). When compared with control subjects, the percentage of positive coronary calcification scores was similar in primary hyperparathyroidism patients (53% vs 50%); however, positive coronary calcification scores were at the 67
CONCLUSION
Positive coronary calcification scores were greater in primary hyperparathyroidism patients than in population-based control subjects. These study data may provide new criteria for parathyroidectomy in patients with primary hyperparathyroidism.

Identifiants

pubmed: 31668778
pii: S0039-6060(19)30612-9
doi: 10.1016/j.surg.2019.05.094
pii:
doi:

Substances chimiques

Parathyroid Hormone 0
Calcium SY7Q814VUP

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

149-154

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Omar Koubaity (O)

Department of Radiology, University of Lorraine, CHU Nancy, Brabois Hospital, France.

Damien Mandry (D)

Department of Radiology, University of Lorraine, CHU Nancy, Brabois Hospital, France.

Phi-Linh Nguyen-Thi (PL)

Medical Evaluation Department, Department of Clinical Research Support PARC, University of Lorraine, CHU Nancy, France.

Florence Bihain (F)

Department of Surgery, Section of Endocrine, Thyroid and Metabolic Surgery, University of Lorraine, CHU Nancy, Brabois Hospital, France.

Claire Nomine-Criqui (C)

Department of Surgery, Section of Endocrine, Thyroid and Metabolic Surgery, University of Lorraine, CHU Nancy, Brabois Hospital, France.

Léa Demarquet (L)

Department of Endocrinology, Diabetology and Nutrition, University of Lorraine, CHU Nancy, France.

Valérie Croise-Laurent (V)

Department of Radiology, University of Lorraine, CHU Nancy, Brabois Hospital, France.

Laurent Brunaud (L)

Department of Surgery, Section of Endocrine, Thyroid and Metabolic Surgery, University of Lorraine, CHU Nancy, Brabois Hospital, France; Nutrition, Genetics, Environmental Risks, Faculty of Medicine, University of Lorraine, INSERM U1256, Nancy, France. Electronic address: l.brunaud@chru-nancy.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH